

CSL-sponsored Symposium  
For Healthcare Professionals Only



# DURABILITY OF GENE THERAPY IN HAEMOPHILIA? BRIDGING TRIAL RESULTS WITH CLINICAL PRACTICE

EAHAD 2026, The Convention Centre Dublin,  
Dublin, Ireland

Wednesday 4 February, 2026 | 14:30–15:30  
Room: Auditorium



**Dr Dalia Khan (Chair)**  
Haemophilia Centre,  
Oxford University Hospital,  
Oxford, United Kingdom



**Dr Jan Astermark**  
Lund University and Skåne  
University Hospital,  
Malmö, Sweden



**Dr David Lillicrap**  
Department of Pathology  
and Molecular Medicine,  
Queen's University,  
Kingston, Ontario, Canada



**Dr Glenn Pierce**  
Vice President (Medical),  
World Federation  
of Hemophilia,  
Quebec, Canada

## AGENDA

Welcome and Introduction <i>Dr Dalia Khan</i>	14:30–14:35
Evaluating Clinical Outcomes in Haemophilia: A Review of Current Data with a Focus on Haemophilia B <i>Dr Jan Astermark</i>	14:35–14:45
Gene Therapy Longevity: Bridging Preclinical Models to Clinical Reality <i>Dr David Lillicrap</i>	14:45–14:55
AAV Gene Therapy Guidelines: Why Now? <i>Dr Glenn Pierce</i>	14:55–15:05
Implementing Guidelines for Gene Therapy in Haemophilia <i>Dr Dalia Khan</i>	15:05–15:15
Closing Remarks and Adjourn <i>Dr Dalia Khan</i>	15:15–15:30

This symposium is organised and funded by CSL. Company products will be discussed. Prescribing and adverse event reporting information will be available at the meeting.

MED-ALL-HGX-00336 | GL-HGX-0029 | January 2026